News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma


Posted on: 01/07/2008

Mon Jan 7, 2008 7:01am EST
 

 Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel
EGFRvIII Vaccine for Glioblastoma



    PHILLIPSBURG, N.J., Jan. 7 /PRNewswire/ -- Celldex Therapeutics announced
today that the U.S. Food and Drug Administration (FDA) has granted Fast Track
designation to Celldex's CDX-110 for the treatment of EGFRvIII expressing
Glioblastoma Multiforme (GBM).  GBM is the most common and aggressive form of
primary brain cancer and carries a very poor prognosis with current therapy.
CDX-110 is an immunotherapy that targets the tumor-specific growth promoter
EGFRvIII that can be expressed by GBM.
    In the ACTIVATE Phase 2a study, GBM patients treated with CDX-110 showed a
median survival time of 30 months, more than a 100 percent increase in
survival, versus the historical control's median of 14.5 months.  The study
has demonstrated a median time-to-progression of 13 months (p=0.0001) versus
the historical control's median of 6.4 months.  GBM that recurred after
treatment with CDX-110 consistently lost EGFRvIII expression with its
aggressive growth signal.  An extension study, ACT II, which combines CDX-110
with chemotherapy in a similar patient population, has not yet reached median
time-to-progression or survival.  Preliminary progression free survival (PFS)
and overall survival (OS) data in ACT II look very similar to the ACTIVATE
experience, and the data suggest that chemotherapy and CDX-110 can be
administered concurrently while still maintaining strong immune responses.
    In September, Celldex randomized its first patient into ACT III, a
definitive Phase 2/3 randomized study of CDX-110 with radiation and
temozolomide in patients with newly-diagnosed GBM.  The clinical trial is
investigating the anticancer activity, impact on survival, and safety of the
addition of CDX-110 vaccine to standard of care, versus standard of care
alone.  Celldex recently announced that CDX-110 has also been granted Orphan
Drug Status by the FDA.  Celldex Therapeutics announced a definitive merger
agreement with AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) in October 2007.
    "Fast Track status acknowledges CDX-110's potential to fill an unmet need
for glioblastoma patients and gives it priority within the FDA," said Thomas
Davis, M.D., Chief Medical Officer of Celldex Therapeutics.  "Confirmation of
the promising results we've already observed is a high priority at Celldex, as
it is within the brain cancer community in general."
    About CDX-110
    CDX-110 is an investigational immunotherapy that targets the tumor
specific molecule EGFRvIII, a functional variant of the epidermal growth
factor receptor (EGFR), which is a protein that has been well validated as a
target for cancer therapy.  This particular variant, EGFRvIII occurs in about
40 percent of Glioblastoma Multiforme (GBM) patients.  It was discovered in a
collaborative effort between Dr. Bert Vogelstein and Dr Albert Wong at Johns
Hopkins University and Dr. Darell Bigner at Duke University.  Unlike EGFR,
EGFRvIII is not present in normal tissues, suggesting this target will enable
the development of a tumor-specific therapy for cancer patients.  Furthermore,
EGFRvIII is a transforming oncogene that can directly contribute to cancer
cell growth.  While originally discovered in GBM, the most common and
aggressive form of brain cancer, the expression of EGFRvIII has also been
observed in various other cancers such as breast, ovarian, metastatic
prostate, colorectal, and head & neck cancers.  Celldex has exclusive rights
to EGFRvIII vaccines and is pursuing the development of CDX-110 for GBM
therapy, as well as in other cancers through additional clinical studies.
    About Fast Track Drug Designation
    Under the FDA Modernization Act of 1997, designation as a Fast Track
product for a new drug or biological products means that FDA will take such
actions as are appropriate to expedite the development and review of the
application for approval of such product.  FDA may also evaluate for filing
and commence review of portions of an application for approval of a Fast Track
product under certain conditions.
    About Celldex Therapeutics, Inc.
    Celldex Therapeutics, Inc. is a biotechnology company focused on
developing therapeutic vaccines that target and stimulate the body's immune
system for the treatment of cancer, infectious and autoimmune diseases.
Celldex has three product candidates already in or about to enter clinical
development targeting multiple cancers and Hepatitis B.  Four additional
product candidates are in preclinical development for cancer and autoimmune
disease.  Celldex's proprietary technology platform uses fully human
monoclonal antibodies administered directly to patients to target and
stimulate dendritic cells - key cells within the immune system.  The Company
is headquartered in Phillipsburg, New Jersey.  On October 22, 2007, Celldex
and AVANT Immunotherapeutics, Inc. announced that they had signed a definitive
merger agreement.  The all-stock transaction, approved by both companies'
Boards of Directors, will combine Celldex and AVANT.  Closing of the merger is
contingent upon a vote of approval by the current stockholders of AVANT at a
special meeting expected to take place in the first quarter 2008.  For more
information, please visit the website: www.celldextherapeutics.com.
    Additional Information about the Merger and Where to Find It This
communication contains "forward-looking" statements within the meaning of the
Private Securities Litigation Reform Act of 1995.  These statements are
typically preceded by words such as "believes," "expects," "anticipates,"
"intends," "will," "may," "should," or similar expressions.  These forward-
looking statements are subject to risks and uncertainties that may cause
actual future experience and results to differ materially from those discussed
in these forward-looking statements.  Important factors that might cause such
a difference include, but are not limited to, costs related to the Merger,
failure of AVANT's stockholders to approve the Merger; AVANT's or Celldex's
inability to satisfy the conditions of the Merger; AVANT's inability to
maintain its NASDAQ listing; the risk that AVANT's and Celldex's businesses
will not be integrated successfully; the combined company's inability to
further identify, develop and achieve commercial success for new products and
technologies; the possibility of delays in the research and development
necessary to select drug development candidates and delays in clinical trials;
the risk that clinical trials may not result in marketable products; the risk
that the combined company may be unable to successfully secure regulatory
approval of and market its drug candidates; the risks associated with reliance
on outside financing to meet capital requirements; risks associated with
Celldex's new and uncertain technology; risks of the development of competing
technologies; risks related to the combined company's ability to protect its
proprietary technologies; risks related to patent-infringement claims; risks
of new, changing and competitive technologies and regulations in the U.S. and
internationally; and other events and factors disclosed previously and from
time to time in AVANT's filings with the Securities and Exchange Commission,
including AVANT's Annual Report on Form 10-K for the year ended December 31,
2006.  The companies do not undertake any obligation to release publicly any
revisions to such forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
    This communication may be deemed to be solicitation material in respect of
the proposed merger of AVANT and Celldex.  In connection with the proposed
merger, AVANT and Celldex intend to file relevant materials with the SEC,
including AVANT's joint registration statement/proxy statement on Form S-4.
SHAREHOLDERS OF AVANT ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE
SEC, INCLUDING AVANT'S PROXY STATEMENT, BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION ABOUT THE PROPOSED TRANSACTION.  Investors and security holders
will be able to obtain the documents free of charge at the SEC's web site,
www.sec.gov, and AVANT shareholders will receive information at an
appropriate time on how to obtain transaction-related documents for free from
AVANT.  Such documents are not currently available.
    Participants in the Solicitation
    The directors and executive officers of AVANT and Celldex may be deemed to
be participants in the solicitation of proxies from the holders of AVANT
common stock in respect of the proposed transaction.  Information about the
directors and executive officers of AVANT is set forth in the proxy statement
for AVANT's most recent 10-K, which was filed with the SEC on March 16, 2007.
Investors may obtain additional information regarding the interest of AVANT
and its directors and executive officers, and Celldex and its directors and
executive officers in the proposed transaction by reading the proxy statement
regarding the acquisition when it becomes available.
SOURCE  Celldex Therapeutics, Inc.

Thomas Davis, Chief Medical Officer of Celldex Therapeutics, Inc.,
+1-908-454-7120; or Dan Budwick of BMC Communications, +1-212-477-9007, ext.
14, for Celldex Therapeutics, Inc.

 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740